AIP & Psychotropic Medications and Low-Dose Naltrexone Supported EMDR Therapy
Psychotropic medications can be very helpful in targeting and decreasing symptoms of Post Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), Depression, Panic Disorder with or without Agoraphobia; Psychotic Disorders, Insomnia related to psychiatric symptoms, and psychological disturbance due to chronic pain syndromes such as fibromyalgia and neuropathy.
This presentation focuses on commonly effective medications useful with symptomatic persons requesting EMDR AIP. Topics include; medications that are first line for people with PTSD and why; medications helpful for reprocessing; off-label medications; medications that may interfere with reprocessing; medication guidelines and suggestions; possible adverse effects; safety and precautions; why medications may appear to be not working; coordination with prescribers; and respond to questions submitted by Western OR EMDRIA members.
It is widely recognized that the endogenous opioid system plays a major role in the mammalian neuro-psycho-biology, but to date, pharmacological interventions affecting this system have been mostly ineffective or carry a burden of serious side effects. While there is promise of better pharmaceuticals to come, it appears that in LDN we already have a medication that safely and effectively reduces psychiatric symptoms through subtle manipulation of the endogenous opioid and related systems.
Using multiple case studies, this session will illustrate how LDN can be used as an adjunct in psychotherapy to address a variety of psychiatric issues, without the side effects associated with other psychotropic medications. LDN can significantly reduce psychiatric symptoms, but its effects are subtle and it is common for patients to discontinue use of the medication even though they may be experiencing a benefit. The presenter will identify a strategy for effectively initiating and maintaining use of LDN for treatment of psychiatric disorders, describe dosing considerations and address safety and medical risks factors. The presentation will explore possible mechanisms of action and identify the potential benefits of a constant partial blockade strategy compared to an intermittent blockade of opioid receptors for reducing dissociative phenomena. Relevant research will be highlighted.